The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
PMDA Reveals Zero Company Request So Far for MID-NET Database Use, but Says Several Interested
No company applied to use the MID-NET large-scale medical information database, which was launched by the Pharmaceuticals and Medical Devices Agency (PMDA) in April, during the first application period through May 15, the PMDA revealed on June 18. “To date…
To read the full story
Related Article
- MSD to Tap MID-NET Database for Erelsa/Grazyna in 3rd Private Sector Use
January 29, 2019
- Pfizer to Use MID-NET Database for Ibrance PMS
September 19, 2018
- Second Applicant from Pharma Companies to Use MID-NET: PMDA
September 19, 2018
- First Drug Maker Applies to Use MID-NET: PMDA
August 7, 2018
- PMDA Reveals First 2 Cases of MID-NET Regulatory Use
July 2, 2018
- PMDA Estimates MID-NET Will Be Used for PMS for 18 Products Annually
March 16, 2018
- PMDA to Take Applications for Using MID-NET Starting April 1
February 27, 2018
REGULATORY
- MHLW Names 77 Active Ingredients for OTC-Like Drug Charges
December 26, 2025
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Japan to Cut Drug Prices by 0.86% in FY2026; Central Govt Savings Seen at 105 Billion Yen
December 25, 2025
- Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…